Search Results
Found 11 results for browse/category/us/en/90217060.
Thermo Fisher Scientific’s Clinical Research Business Wins Clinical Research Company of the Year Title for Fourth Consecutive Year, Receives Multiple Honors at PharmaTimes Competitions
The PPD clinical research business of Thermo Fisher Scientific, the world leader in serving science, has been recognized for excellence in clinical research at the 2023 PharmaTimes Clinical Researcher of the Year competitions.
New and Emerging Regulatory Guidance for Cell and Gene Therapy Product Development
Considerations for cell and gene therapy development have shifted based on recent updates published by the EMA and FDA. Here’s a brief summary of the new guidance.
Peri and Post-Approval
Biopharmaceutical companies are needing more and more evidence to prove value and effectiveness in post-approval settings, including how to communicate this evidence to payers, health authorities and other decision-makers.
Vaccine Development
PPD has worked in vaccine development for more than 30 years, offering full-service capabilities.
RACE Act: A Promising Catalyst for Improved Pediatric Cancer Treatments
Developing targeted therapies for children in oncology has taken on a significantly higher priority now that the RACE ACT is in effect.